Anixa Biosciences Announces Issuance of Canadian Patent For Its CAR-T Cancer Therapy Technology
Portfolio Pulse from Happy Mohamed
Anixa Biosciences, Inc. (NASDAQ:ANIX) has been granted a Canadian patent for its Chimeric Antigen Receptor-T cell (CAR-T) cancer treatment technology. The technology, which is currently being evaluated for the treatment of ovarian cancer in a Phase 1 clinical trial, has been licensed from The Wistar Institute and is being developed in partnership with Moffitt Cancer Center. The patent covers a nucleic acid that encodes a chimeric protein used to treat certain types of cancer.
July 11, 2023 | 12:51 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Anixa Biosciences has secured a Canadian patent for its CAR-T cancer treatment technology. This could potentially strengthen the company's intellectual property portfolio and increase its market competitiveness.
The issuance of a patent for Anixa's CAR-T technology could potentially enhance the company's market position by strengthening its intellectual property rights. This could also attract more investors, potentially leading to a short-term increase in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100